Elahi Leslie, Zellweger Matthieu, Abdelnour-Berchtold Etienne, Gonzalez Michel, Ris Hans-Beat, Krueger Thorsten, Raffoul Wassim, Perentes Jean Yannis
Department of Thoracic Surgery, University Hospital of Lausanne (CHUV), Lausanne, Switzerland.
Department of Plastic, Reconstructive and Hand Surgery, University Hospital of Lausanne (CHUV), Lausanne, Switzerland.
Transl Cancer Res. 2022 May;11(5):1162-1172. doi: 10.21037/tcr-21-2143.
Chest wall resections/reconstructions are a validated approach to manage tumors invading the thorax. However, how resection characteristics affect postoperative morbidity and mortality is unknown. We determined the impact of chest wall resection size and location on patient short and long-term postoperative outcomes.
We reviewed all consecutive patients who underwent resections/reconstructions for chest wall tumors between 2003 and 2018. The impact of chest wall resection size and location and reconstruction on perioperative morbidity/mortality and oncological outcome were evaluated for each patient.
Ninety-three chest wall resections were performed in 88 patients for primary (sarcoma, breast cancer, n=66, 71%) and metastatic (n=27, 29%) chest wall tumors. The mean chest bony resection size was 107 (range, 15-375) cm and involved ribs only in 57% (n=53) or ribs combined to sternal/clavicular resections in 43% of patients (n=40). Chest defect reconstruction methods included muscle flaps alone (14%) prosthetic material alone (25%) or a combination of both (61%). Early systemic postoperative complications included pneumonia (n=15, 16%), atelectasis (n=6, 6%), pleural effusion (n=15, 16%) and arrhythmia (n=6, 6%). The most frequent long-term reconstructive complications included wound dehiscence (n=4), mesh infection (n=5) and seroma (n=4). Uni- and multivariable analyses indicated that chest wall resection size (>114 cm) and location (sternum) were significantly associated with the occurrence of pneumonia and atelectasis [odds ratio (OR) =3.67, P=0.05; OR =78.92, P=0.02, respectively]. Disease-free and overall survival were 37±43 and 48±42 months for primary malignancy and of 24±33 and 48±53 months for metastatic chest wall tumors respectively with a mean follow-up of 46±44 months.
Chest wall resections present good long-term oncological outcomes. A resection size above 114 cm and the involvement of the sternum are significantly associated with higher rates of postoperative pneumonia/atelectasis. This subgroup of patients should have reinforced perioperative physical therapy protocols.
胸壁切除/重建是治疗侵犯胸部肿瘤的一种有效方法。然而,切除特征如何影响术后发病率和死亡率尚不清楚。我们确定了胸壁切除大小和位置对患者术后短期和长期结果的影响。
我们回顾了2003年至2018年间所有因胸壁肿瘤接受切除/重建的连续患者。评估了每位患者胸壁切除大小、位置和重建对围手术期发病率/死亡率及肿瘤学结果的影响。
88例患者共进行了93次胸壁切除术,治疗原发性(肉瘤、乳腺癌,n = 66,71%)和转移性(n = 27,29%)胸壁肿瘤。胸壁骨切除的平均大小为107(范围15 - 375)cm,57%(n = 53)的患者仅累及肋骨,43%(n = 40)的患者肋骨联合胸骨/锁骨切除。胸壁缺损重建方法包括单独使用肌瓣(14%)、单独使用假体材料(25%)或两者联合使用(61%)。术后早期全身并发症包括肺炎(n = 15,16%)、肺不张(n = 6,6%)、胸腔积液(n = 15,16%)和心律失常(n = 6,6%)。最常见的长期重建并发症包括伤口裂开(n = 4)、网片感染(n = 5)和血清肿(n = 4)。单变量和多变量分析表明,胸壁切除大小(>114 cm)和位置(胸骨)与肺炎和肺不张的发生显著相关[比值比(OR)= 3.67,P = 0.05;OR = 78.92,P = 0.02]。原发性恶性肿瘤的无病生存期和总生存期分别为37±43个月和48±42个月,转移性胸壁肿瘤分别为24±33个月和48±53个月,平均随访46±44个月。
胸壁切除术具有良好的长期肿瘤学结果。切除大小超过114 cm和累及胸骨与术后肺炎/肺不张的发生率显著升高相关。这一亚组患者应加强围手术期物理治疗方案。